Dr Scott North
Professor & Division Director
Medical Oncology
Department of Oncology
University of Alberta
Cross Cancer Institute

“Improving Outcomes in Advanced Bladder Cancer Through Multidisciplinary Care”

Wednesday
May 11, 2016
12:00 to 13:00
GLEN Site
Room D02.4250
Visioconference: vspo@mcgill.ca

Wednesday
May 11, 2016
17:00 to 18:00
Notre-Dame Hospital
Amphithéâtre Deschamps

Thursday
May 12, 2016
12:00 to 13:00
Charles Le Moyne Hospital
Room HN 106
Live on the Web: www.vpsolution.tv/vspo
Problems/Questions: 514 813-4510

Learning Objectives
• Discuss standard of care issues in the multidisciplinary management of muscle-invasive bladder cancer with a special focus on logistical pearls to optimize care
• Identify the appropriate patient with locally advanced bladder cancer that may be treated by bladder sparing-surgery, including the option of chemoradiation
• Discuss new paradigms in the treatment of metastatic urothelial carcinoma in the era of emerging immunotherapy options
• What is the best chemotherapy radiosensitizer in cisplatin um fit and unfit patient?

This event is approved for up to 1 credit by the Office for Continuing Professional Development. The Office for CPD, Faculty of Medicine, McGill University is fully accredited by the Committee on Accreditation of Canadian Medical Education (CACME). This event is an Accredited Group Learning Activity as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada. Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert Royal College MOC credit to AMA credit can be found at www.amaassn.org/go/internationalcme. Each physician should claim only credit commensurate with the extent of their participation in the activity. For more information, please visit our website at: http://www.medicine.mcgill.ca/oncology/speakers/speakers_visitingspeakers.asp

This program has received an educational grant from:
Astellas, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eisai, Gilead, Janssen, Lilly Oncology, Lundbeck, Merck, Novartis, Pfizer, Roche